Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	PMV Pharmaceuticals	Applied Molecular Transport	Zealand Pharma A/S	Theravance Biopharma	Indivior
Symbol	NASDAQ:PMVP	NASDAQ:AMTI	NASDAQ:ZEAL	NASDAQ:TBPH	OTCMKTS:INVVY
Price Information
Current Price	$32.09	$44.70	$29.00	$18.72	$10.31
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	2.0	1.2	1.6	0.8
Analysis Score	2.4	3.5	3.5	3.5	0.0
Community Score	2.9	3.6	2.5	2.4	1.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	2.5	0.0	1.7	0.0
Earnings & Valuation Score	0.0	0.6	0.0	0.6	1.9
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$38.00	$68.75	$43.00	$31.33	N/A
% Upside from Price Target	18.42% upside	53.80% upside	48.28% upside	67.38% upside	N/A
Trade Information
Market Cap	$1.44 billion	$1.58 billion	$1.26 billion	$1.22 billion	$1.51 billion
Beta	N/A	N/A	1.19	0.94	0.3
Average Volume	163,194	227,360	11,822	332,904	8,310
Sales & Book Value
Annual Revenue	N/A	N/A	$6.20 million	$73.41 million	$785 million
Price / Sales	N/A	N/A	203.23	16.65	1.93
Cashflow	N/A	N/A	N/A	N/A	$2.06 per share
Price / Cash	N/A	N/A	N/A	N/A	5.01
Book Value	N/A	N/A	$5.85 per share	($3.94) per share	$1.43 per share
Price / Book	N/A	N/A	4.96	-4.75	7.21
Profitability
Net Income	N/A	$-28,040,000.00	$-85,670,000.00	$-236,460,000.00	$134 million
EPS	N/A	N/A	($2.54)	($4.25)	$1.15
Trailing P/E Ratio	0.00	0.00	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	17.47
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-214.31%	-345.16%	-31.93%
Return on Equity (ROE)	N/A	N/A	-38.34%	N/A	-4.15%
Return on Assets (ROA)	N/A	N/A	-30.40%	-51.60%	-0.26%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	2.89%
Current Ratio	N/A	19.39%	6.76%	4.32%	1.82%
Quick Ratio	N/A	19.39%	6.51%	4.32%	1.69%
Ownership Information
Institutional Ownership Percentage	69.72%	51.99%	4.32%	80.41%	N/A
Insider Ownership Percentage	N/A	N/A	N/A	5.90%	N/A
Miscellaneous
Employees	44	80	329	359	788
Shares Outstanding	44.93 million	35.25 million	43.45 million	65.28 million	146.92 million
Next Earnings Date	8/13/2021 (Estimated)	8/10/2021 (Estimated)	8/12/2021 (Estimated)	8/5/2021 (Estimated)	N/A
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Drug Addiction Treatment Market 2026 Industry Specifications and Outlook 2021 \|Indivior, Pfizer, Alkermes, Novartis, Mylan – Brockville Observer - Brockville Observer thebrockvilleobserver.ca - May 15 at 12:28 PM
	Idaho among states to reach $300 million settlement with drug company Indivior - Idaho State Journal idahostatejournal.com - May 14 at 3:00 PM
	WV to get more than $5M in settlement over marketing of opioid withdrawal drug Suboxone - The Logan Banner loganbanner.com - May 12 at 1:29 AM
	WV to get more than $5M in settlement over marketing of opioid withdrawal drug Suboxone - Huntington Herald Dispatch herald-dispatch.com - May 9 at 12:43 AM
	NJ Gets Share Of $300M Opioid Treatment Settlement - Patch.com patch.com - May 7 at 6:28 PM
	ATTORNEY GENERAL SCHMITT ANNOUNCES SETTLEMENT WITH INDIVIOR OVER FALSE MARKETING RELATED TO SUBOXONE - kmmo.com kmmo.com - May 7 at 1:16 PM
	Healey Secures $6.65 Million from Drug Company for False Marketing - CapeCod.com News capecod.com - May 7 at 8:16 AM
	Rio Tinto and Indivior investors revolt over executive pay awards - The Times thetimes.co.uk - May 7 at 8:16 AM
	Indivior hit by investor rebellion over payout to former CEO - Nasdaq nasdaq.com - May 6 at 7:14 PM
	UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs - Morningstar morningstar.co.uk - May 6 at 2:14 PM
	Attorney General Schmitt Announces Settlement with Indivior Over False Marketing Related to Suboxone - EIN News einnews.com - May 6 at 2:14 PM
	Thursday newspaper round-up: Covid contracts, Indivior, KPMG, Glaxo - ShareCast sharecast.com - May 6 at 3:39 AM
	Attorney General Morrisey reaches settlement involving opioid withdrawal drug - WBOY.com wboy.com - May 5 at 7:38 AM
	Momentum investing with Indivior (LON:INDV) - Stockopedia stockopedia.com - May 5 at 7:38 AM
	W.Va. AG announces settlement over false claims - Parkersburg News newsandsentinel.com - May 5 at 1:36 AM
	Indivior faces shareholder ire over bonus for imprisoned ex-CEO finance.yahoo.com - May 5 at 1:36 AM
	Study: 1 in 5 Pharmacies Blocks Access to Addiction Treatment Buprenorphine - Pharmacy Times pharmacytimes.com - May 3 at 1:22 PM
	WV to receive more than $5.2M in pharmaceutical company settlement - WOWK 13 News wowktv.com - May 3 at 1:22 PM
	Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021 - StreetInsider.com streetinsider.com - May 3 at 8:21 AM
	Indivior PLC's (INVVY) CEO Mark Crossley on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - May 1 at 1:35 PM
	Md AG Announces $300 Million Settlement with Drug Distributor - WCBC Radio wcbcradio.com - May 1 at 8:35 AM
	AG Cameron announces $300 million multistate settlement with Indivior - ABC 36 News - WTVQ wtvq.com - April 30 at 7:47 PM
	Drug Addiction Treatment Market Insight and Forecast to 2026 \| Indivior, Pfizer, Alkermes, Novartis – Good News Gum - Good News Gum goodnewsgum.com - April 30 at 2:46 PM
	Attorney General Moody Secures $300 Million Following Investigation into Improper Marketing and Sale of Suboxone - EIN News einnews.com - April 30 at 2:46 PM
	Indivior swings into profit - Capital.com capital.com - April 29 at 9:34 AM

Date	Company	Brokerage	Action
10/20/2020	PMV Pharmaceuticals	Evercore ISI	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	Bank of America	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	The Goldman Sachs Group	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	Cowen	Initiated Coverage
3/23/2021	Applied Molecular Transport	Jefferies Financial Group	Boost Price Target
3/23/2021	Applied Molecular Transport	JMP Securities	Initiated Coverage
2/25/2021	Applied Molecular Transport	SVB Leerink	Boost Price Target
11/13/2020	Zealand Pharma A/S	Morgan Stanley	Lower Price Target
8/13/2020	Zealand Pharma A/S	Needham & Company LLC	Initiated Coverage
9/19/2019	Zealand Pharma A/S	Guggenheim	Initiated Coverage
11/6/2020	Theravance Biopharma	HC Wainwright	Reiterated Rating
8/7/2020	Theravance Biopharma	Piper Sandler	Lower Price Target
7/7/2020	Theravance Biopharma	JPMorgan Chase & Co.	Initiated Coverage
7/27/2020	Indivior	Citigroup	Upgrade
7/27/2020	Indivior	Stifel Nicolaus	Upgrade

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources